Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more
DYN is expected to report earnings to fall 10.42% to -94 cents per share on July 31
Q2'25
Est.
$-0.94
Q1'25
Missed
by $0.20
Q4'24
Beat
by $0.06
Q3'24
Missed
by $0.25
Q2'24
Beat
by $0.02
The last earnings report on May 08 showed earnings per share of -104 cents, missing the estimate of -85 cents. With 561.69K shares outstanding, the current market capitalization sits at 1.33B.